Investing News

Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug

Cytokinetics Inc. reported positive results Wednesday from a key Phase 3 study of its experimental drug to treat heart disease.

Articles You May Like

Oracle Stock: Buy Now and Hold Tight for the AI and Healthcare Gold Rush
First Berkshire Hathaway annual meeting without Charlie Munger: What to expect from Warren Buffett
3 Speculative Stocks That Could Make You a Fortune (if You Dare)
Exxon Mobil reaches agreement with FTC, poised to close $60 billion Pioneer deal
3 Steady Stocks Predicted to Double in Value by 2026